
19 November 2026
Scancell Holdings plc
(“Scancell”, the “Company” or the “Group”)
Result of Annual General Meeting
Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk) is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody® and Moditope® platforms, designed to stimulate durable anti-tumor responses. The lead product, inzitagene plasmivec, is a DNA ImmunoBody® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1 is a Moditope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell is advancing a pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
For more information please contact:
Scancell Holdings plc | |
Phil L’Huillier, CEO | |
Panmure Liberum (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Emma Earl, Will Goode, Mark Rogers | |
WG Partners LLP (Joint Broker) Claes Spang | +44 (0) 20 3705 9330 |
Investor and media relations Mandeep Sehmi | mandeepsehmi@scancell.co.uk |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
